MILAAN–(BUSINESS WIRE)– Aan de Series A-ronde hebben voormalige aandeelhouders deelgenomen en een belangrijke bijdrage geleverd van nieuwe investeerders: Italiaanse business angels, family office en anderen. I-VASC is van plan de opbrengst van deze ronde te gebruiken om post-market klinische studies uit te voeren, FDA-goedkeuring te verkrijgen voor de Amerikaanse markt en volledige productindustrialisatie.

I-VASC Srl, in Italië gevestigd bedrijf voor medische hulpmiddelen, dat een nieuwe technologie heeft bedacht voor de behandeling van CVI en spataderen genaamd EVA (Empty Vein Ablation) en het VELEX ™ -apparaat heeft ontwikkeld op basis van deze technologie, heeft aangekondigd dat het met succes zijn Series A-financieringsronde, overtekend door een groot aantal investeerders, waaronder met name Luca Trevisan, Bootes (Rosario Bifulco) en Nalini family Office, en andere gekwalificeerde investeerders. Naast de tranche van 750K euro die in de eerste helft van 2021 is opgehaald, heeft het bedrijf voor het einde van vorig jaar nog een tranche van 1,066 miljoen euro opgehaald, voor een totaal bedrag van 1,8 miljoen euro in 2021. De opbrengst van deze ronde zal worden gebruikt door I-VASC om te betalen voor klinische onderzoeken na het op de markt brengen van het VELEX ™ -apparaat (dat in mei 2021 CE-markering heeft gekregen voor de Europese markt), om over te gaan naar goedkeuring door de regelgevende instanties van de FDA voor de Amerikaanse markt, en de industrialisatie gedurende een hele levering te consolideren keten van gekwalificeerde leveranciers. Het bedrijf heeft ook de benoeming aangekondigd van twee nieuwe bestuurders in de raad van bestuur om het managementteam in deze fase van strategische groei te versterken: Daniele Zanotti, die de rol van CEO op zich heeft genomen, en Cristiano Fontana, die verantwoordelijk is voor bedrijfsontwikkeling, marketing en communicatie. Mario Salerno, oprichter van I-VASC en uitvinder van de EVA-technologie, zal zijn actieve uitvoerende rol en de functies van voorzitter van de raad van bestuur en voorzitter behouden, terwijl Emilio Roncoroni en Attilio Castelli van het vorige bestuur hun rol van respectievelijk Chief Administration en Chief Technology Officers.

I-VASC Srl Announces achievement of 1,8M € Series A investment to launch its product, VELEX™, a device for the treatment of Chronic Venous Insufficiency (CVI)

MILAN–(BUSINESS WIRE)– The Series A round has seen the participation of former shareholders and a significant contribution of new investors: Italian business angels, family office and others. I-VASC is planning to use the proceeds from this round to execute post-market clinical studies, to obtain FDA approval for the US market and complete product industrialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005835/en/

VELEX™, A novel device for the treatment of Chronic Venous Insufficiency (CVI) (Photo: Business Wire)

I-VASC Srl, Italy based medical device company, which has conceived a new technology for the treatment of CVI and varicose veins named EVA (Empty Vein Ablation) and developed the VELEX ™ device based on this technology, has announced that it has successfully finalized its Series A financing round, oversubscribed by a high number of investors, including notably the Luca Trevisan, Bootes (Rosario Bifulco), and Nalini family Office, and others qualified investors. In addition to the 750K Euro tranche raised in the first half of 2021, the company has raised another 1.066M Euro tranche before the end of last year, for a total amount of 1.8M Euro in 2021. The proceeds from this round will be used by I-VASC to pay for post-market clinical studies of the VELEX ™ device (which has received CE Mark approval for the European market in May 2021), to move toward FDA regulatory approval for the US market, and consolidate industrialization throughout a supply chain of qualified suppliers. The company has also announced the appointments of two new Directors in its board to reinforce its management Team in this phase of strategic growth: Daniele Zanotti, who has assumed the role of CEO, and Cristiano Fontana, who has undertaken responsibility for business development, marketing and communication. Mario Salerno, founder of I-VASC and inventor of the EVA technology, will retain his active executive role and the functions of Chairman of the Board and President, while Emilio Roncoroni and Attilio Castelli from the previous board, will continue to exert their roles of Chief Administration and Chief Technology Officers, respectively.

“Thanks to the investors, who have believed in our proprietary and innovative technology, and to our reinforced team, we are now on the verge to bring VELEX™ into the market.”

VELEX™, I-VASC’s first CE Mark approved device, offers the innovative solution of the Empty Vein Ablation (EVA) technology for treating CVI, which notably includes the varicose veins disease.

VELEX™ innovation consists of a percutaneous 3-ballon catheter that allows to perform a chemical ablation (Schlerotherapy) into the portion of the vein to be treated after having isolated it and emptied it from blood. This method offers the ability of fully controlling schlerosant agent contact distribution and time, resulting into optimal ablation results. Besides, agent segregation, limited concentration and final retrieval may result also in superior safety, when compared to conventional schlerotherapy.

“I am thrilled to embrace this new professional adventure and put my experience at the service of a project which has the potential of representing a new paradigm in the largely underserved market of CVI and varicose vein. With the considerable efficacy, safety and usability improvements that VELEX can offer with respect to all alternative methods, we have the opportunity to offer a better option to millions of patients and create a huge new value in the vascular arena.” said Daniele Zanotti, newly appointed CEO of I-VASC.

“We are approaching a new and important phase of the project, which I started in 2015. Thanks to the investors, who have believed in our proprietary and innovative technology, and to our reinforced team, we are now on the verge to bring VELEX™ into the market and provide proof of the validity of our EVA (Empty Vein Ablation) procedure” said Mario Salerno, Founder and CMO of I-VASC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005835/en/

Contacts

Media Inquiries:

Ella Gilani

Executive assistant and Operations

e.gilani@i-vasc.com
+39 324 0873066

www.i-vasc.com